Ibio Inc IBIO

Healthcare Biotechnology

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

NYSEAM:IBIO - Post by User

Ibio Inc > Getting noticed

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Jul 20, 2020 12:00pm

154 Views

Post# 31290817

RE:RE:Getting noticed

Pandora wrote:

Pandora wrote: IBIO has come back to life after a number of down weeks. As development on all fronts slowly emerge on either a drug side or a manufacturing side it is betting noticed. Volumes are running high.

Two months later I guess I can just repeat what I said above! :-))

July 20 - big jump this morning on no news.

IBIO has one of the larger vaccine manufacturing facilities in the U.S. and a process called Fast Pharming which will allow them to manufacture a high number of doses regardless of whose vaccine it happens to be.

In addition they are also working with the University of Texas on two vaccines of their own.

Will it run once news comes out???

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle